The HMG-CoA reductase inhibitors simvastatin and lovastatin are highly dependent on CYP3A for metabolism, thus concomitant use of Kaletra with simvastatin or lovastatin is not recommended due to an increased risk of myopathy including rhabdomyolysis.
HMG- CoA reduktaasi inhibiitorite simvastatiini ja lovastatiini metabolism sõltub oluliselt CYP3A- st, seetõttu ei soovitata neid ravimeid müopaatia (sh. ka rabdomüolüüsi) tekkeohu suurenemise tõttu samaaegselt Kaletra’ ga kasutada.